Multi-modal benefits of deramiocel (CAP-1002) in late-stage patients with DMD: a new treatment approach to target skeletal and cardiac muscle pathogenesis (HOPE 2-OLE trial: 36-month data) (WMS 2024)
Craig M. McDonald, M.D., Chet Villa, M.D., Jonathan H. Soslow, M.D., Cuixia Tian, M.D., Alexander M. Zygmunt, M.D., Nicholas J. Ollberding, Ph.D., Kan N. Hor, M.D., Matthew M. Harmelink, M.D., Arun S. Varadhachary, M.D., Ph.D., Susan Apkon, M.D., Veena Ramanna, Upagna Desai, Nathaniel J. Hogan, Ph.D., Kati S. Maharry, Ph.D., Mark S. Awadalla, Linda Marbán, Ph.D.
View Article